Table 5.
Logistic regression model for predictors of tumor responder
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| OR | 95% CI | P-value | OR | 95% CI | P-value | |
| Age ≥65 y/o (vs. <65 y/o) | 0.407 | 0.146-1.129 | 0.084 | |||
| Male (vs. female) | 0.400 | 0.112-1.432 | 0.159 | |||
| ECOG 0 (vs. 1/2) | 2.050 | 0.754-5.577 | 0.160 | |||
| Viral infection (vs. others) | 2.500 | 0.289-21.60 | 0.405 | |||
| Child-Pugh grade A (vs. B) | 1.792 | 0.360-8.932 | 0.476 | |||
| ALBI grade I (vs. II/III) | 1.423 | 0.522-3.882 | 0.491 | |||
| Portal vein thrombosis (vs. No) | 0.525 | 0.191-1.442 | 0.211 | |||
| Extrahepatic metastasis (vs. No) | 0.712 | 0.252-2.006 | 0.520 | |||
| AFP≥400 ng/ml (vs. <400 ng/ml) | 0.475 | 0.172-1.308 | 0.150 | |||
| BCLC stage B (vs. C) | 2.154 | 0.745-6.231 | 0.157 | |||
| Beyond up-to-7 criteria (vs. within) | 0.618 | 0.166-2.309 | 0.474 | |||
| First line (vs. second line or later) | 2.750 | 0.945-8.002 | 0.063 | |||
| CRAFITY score low (vs. high) | 1.939 | 1.444-8.476 | 0.039 | 1.763 | 1.387-8.037 | 0.044 |
| ≥75% AFP decrease or ≤10% AFP increase at 6 weeks (vs. No) | 9.194 | 1.969-42.93 | 0.005 | 3.881 | 1.732-20.57 | 0.011 |
| Prior loco-regional therapy (vs. No) | 1.581 | 0.583-4.290 | 0.368 | |||
| IrAE (vs. No) | 1.316 | 0.466-3.716 | 0.604 | |||
Abbreviations: AFP, Alpha-fetoprotein; ALBI, Albumin-bilirubin index; BCLC, Barcelona Clinic Liver Cancer; CRAFITY, CRP and AFP in Immunotherapy; ECOG, Eastern Cooperative Oncology Group; IrAE, Immunotherapy related adverse events.